Navigation Links
Reportlinker Adds Pharmaceutical Key Trends 2011 - Biosimilar Market Overview

NEW YORK, April 28, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Pharmaceutical Key Trends 2011 – Biosimilar Market Overview–-Biosimilar-Market-Overview.html


In 2009, the combined biosimilars market size for the US and five major European markets was $150m. With more than 30 branded biologics with sales of $51bn set to lose patent exclusivity between 2011 and 2015, Datamonitor forecasts that the global biosimilar market will grow from $243m in 2010 to $3.7bn in 2015.

Features and benefits

* Overview of the biosimilar market, with biosimilar definitions in the US, EU and Japan, plus historical and forecast biosimilar sales out to 2015.

* Insight into the key drivers and resistors to biosimilar uptake in the developed and emerging markets.

* Assesses key factors determining successful biosimilar market access, and examines the major biosimilar players and the strategies they implement.

* Analyses biosimilar uptake in the five main European markets and provides insight into the future opportunities for biosimilar players.


Due to their complexity, cost, and development risks, biosimilar production and commercialization in developed markets is concentrated among only a handful of pharma companies, all of which are established generics players.

Despite the Introduction of approval pathways in the US, EU, and Japan, the growing use of biologics, and the need for more cost-effective treatments, all of which help drive biosimilar uptake, there remain a large number of barriers to uptake.

There are relatively few factors which limit the growth of the biosimilar industry in the developing markets, although the Introduction of biosimilar pathways will restrict market access to many domestic biosimilar players, while low purchasing power and a high proportion of out-of-pocket expenditure, coupled with brand loyalty, limit access.

Your key questions answered

* Evaluate the evolving regulatory environment in the US, EU and Japan, and how this impacts biosimilar market access and uptake.

* Gain insight into the deal types among branded, generic and biosimilars players to either enter or bolster their position in the biosimilars market.

* Identify which branded biologics are facing patent expiry and provide significant opportunities for biosimilar developers.

Executive Summary


Strategic scoping and focus

Key findings

Related reports

Upcoming related reports


[Missing title]

Biosimilar definitions

Biosimilar sales in 2009

Biologic sales exposed to potential biosimilar competition during 2011–15

Forecast biosimilar sales, 2010–15

Profitability of biosimilars versus branded biologics and generics


Drivers and resistors to biosimilar uptake in the developed markets

Drivers of biosimilar uptake in developed markets

Neutral factors impacting biosimilar uptake in developed markets

Resistors to biosimilar uptake in developed markets

Drivers and resistors to biosimilar uptake in Brazil, Russia, India, and China

Drivers of biosimilar uptake in emerging markets

Resistors impacting biosimilar uptake in emerging markets


Key factors in determining the success of biosimilar market access

Biosimilar development timeline

Biosimilar development costs

Pros and cons of developing and manufacturing biosimilars in developing markets

Biosimilar approval pathways

Biosimilar producers face a challenging patent environment

Biosimilar pricing in developed markets

Partnerships help drive growth of the biosimilars industry


Key biosimilar players in the developed and emerging markets

Key biosimilar players in the developed markets

Key players in the emerging markets


Biosimilar launches

US biosimilars market

Biosimilars in the five major EU markets

Japanese biosimilars market

Australian biosimilars market

BRIC biosimilars market


Uptake of biosimilar somatropin, filgrastim and epoetin

Biosimilar somatropin

Biosimilar filgrastim

Biosimilar epoetin


Branded biologic patent expiries present opportunities for the biosimilar industry

Biologic patent expiries in the US

Biologic patent expiries in the five major EU markets

Biologic patent expiries in Japan

Biosimilars in development internationally

Biosimilar MAbs and second-generation biosimilars offer the greatest commercial potential


Publications and online articles


Exchange rates used in this report

To order this report:

: Pharmaceutical Key Trends 2011 – Biosimilar Market Overview

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding them ... a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to provide ... need to turn on a light when taking medication during the night, allowing the ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
Breaking Medicine News(10 mins):